GAL-021

• Description:

  GAL-021 is a potent BKCa-channel blocker. GAL-021 inhibits KCa1.1 in GH3 cells. GAL-021 is a novel breathing control modulator that is based on selective modification of the almitrine pharmacophore. GAL-021 increases minute ventilation in rats and non-human primates[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  Potassium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/GAL-021.html

• Purity:

  99.93

• Solubility:

  DMSO : ≥ 30 mg/mL

• Smiles:

  CCCNC1=NC (N (OC) C) =NC (NCCC) =N1

• Molecular Formula:

  C11H22N6O

• Molecular Weight:

  254.33

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Golder FJ, et al. Identification and Characterization of GAL-021 as a Novel Breathing Control Modulator. Anesthesiology. 2015 Nov;123 (5) :1093-104.|[2]J F McLeod, et al. GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers. Br J Anaesth. 2014 Nov;113 (5) :875-83.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1380341-99-0